HKSE:01541'
s EV-to-Revenue Range Over the Past 10 Years
Min: 10671.09 Med: 15769.99 Max: 22622.82
Current: 11200.59
During the past 3 years, the highest EV-to-Revenue of ImmuneOnco Biopharmaceuticals (Shanghai) was 22622.82. The lowest was 10671.09. And the median was 15769.99.
HKSE:01541's EV-to-Revenue is ranked worse than 99.23% of 1038
companies
in the Biotechnology industry
Industry Median: 8.22
vs HKSE:01541: 11200.59
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ImmuneOnco Biopharmaceuticals (Shanghai) Annual Data
Trend
Dec21
Dec22
Dec23
EV-to-Revenue
-
-
25,126.72
ImmuneOnco Biopharmaceuticals (Shanghai) Semi-Annual Data
Dec21
Jun22
Dec22
Jun23
Dec23
EV-to-Revenue
-
-
-
-
25,126.72
Competitive Comparison of ImmuneOnco Biopharmaceuticals (Shanghai)'s EV-to-Revenue
For the Biotechnology subindustry, ImmuneOnco Biopharmaceuticals (Shanghai)'s EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ImmuneOnco Biopharmaceuticals (Shanghai)'s EV-to-Revenue Distribution in the Biotechnology Industry
ImmuneOnco Biopharmaceuticals (Shanghai)'s current Enterprise Value is HK$4,726.65 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. ImmuneOnco Biopharmaceuticals (Shanghai)'s Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.42 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ImmuneOnco Biopharmaceuticals (Shanghai)'s share price for today is HK$14.60.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ImmuneOnco Biopharmaceuticals (Shanghai) EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of ImmuneOnco Biopharmaceuticals (Shanghai)'s EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Business Description
ImmuneOnco Biopharmaceuticals (Shanghai) Inc is a science-driven biotechnology company dedicated to the development of immuno-oncology therapies. It is one of the few biotechnology companies globally adopting a systematic approach to harness both the innate and adaptive immune systems. It has developed a rich pipeline of 14 drug candidates with eight ongoing clinical programs, featured by a comprehensive innate-immunity-based asset portfolio. Its pipeline reflects its extensive understanding of the frontiers of cancer biology and immunology and its expertise in turning scientific research into drug candidates.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:01541 has been successfully added to your